Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March 26, 2012
WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ — Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 26, 2012, at 5:00 p.m. EDT to provide a business update and discuss its fourth quarter 2011 financial results.
To participate in the call, please dial 1-800-638-4930 (domestic) or 1-617-614-3944 (international) and reference access code 34844557.
The conference call can be accessed from the Investors section of the Company’s website or directly at http://edge.media-server.com/m/p/o4v89uyi/lan/en. The webcast will also be archived on the website.
Tengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Using its Organ Regeneration Platform(TM), the Company creates neo-organs using a patient’s own cells, or autologous cells. Tengion’s proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit(TM), an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical candidate is the Neo-Kidney Augment(TM), which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.